Re-Vana Therapeutics
Dr. Levy is CEO of OcuNexus Therapeutics, a biopharmaceutical company developing novel and differentiated products in ophthalmology. Prior to OcuNexus he was Chief Medical Officer (CMO) at Aerie Pharmaceuticals where he developed Rho kinase inhibitors for the lowering of intraocular pressure (IOP) in patients with glaucoma. Previously, he served as corporate vice president of R&D and CMO at Bausch + Lomb where he was responsible for three new drug applications (NDAs) for pharmaceuticals Retisert®, Zylet®, and Besivance®, all of which are now FDA approved. Dr. Levy also was Associate Professor, Department of Ophthalmology at California Pacific Medical Center in San Francisco, in private practice in Toronto and served as clinical investigator and consultant to the ophthalmic industry.
This person is not in the org chart
This person is not in any offices
Re-Vana Therapeutics
Re-Vana Therapeutics is an ocular pharmaceutical and drug delivery company focused on the development and commercialisation of revolutionary long-acting biodegradable drug delivery platforms to treat chronic eye diseases such as age-related macular degeneration, diabetic retinopathy, glaucoma and ocular infections.